Arun S. Singh, MD
In a heavily pretreated patient population with gastrointestinal stromal tumors (GIST), durable responses and disease control were observed with single-agent and combination immunotherapy, according to results of a phase II randomized trial presented at the 2018 Gastrointestinal Cancers Symposium.
, Singh discussed the developing role of immunotherapy in patients with GISTs, particularly the randomized phase II trial investigating nivolumab as a single agent and in combination with ipilimumab.
OncLive: What was the rationale behind conducting this trial?
: GIST is a rare group of tumors that could start anywhere in the gastrointestinal tract. The 2 most common locations are in the stomach and the small intestine. Traditionally, they are treated with surgery and more advanced or metastatic GISTs are treated with TKIs. There are 3 drugs that are FDA approved for GISTs, including imatinib (Gleevec), sunitinib (Sutent), and regorafenib (Stivarga). However, there are new exciting compounds currently in clinical trials. Our study is one of the few studies focused on immunotherapy in patients with GISTs.
What was the design of this trial?
This is a parallel design trial. A way to think of this trial is as 2 individual trials ongoing at the same time. While it is a randomized trial, the 2 arms are not actually compared to each other. We are looking for how well a patient responds to nivolumab alone, as well as how they respond to nivolumab in combination with ipilimumab.
What were the significant findings?
The group of patients in this trial have advanced disease. The median number of previous therapies that were received was 4. That is quite a lot of treatment for these patients. So far, we have seen that one-third of patients received clinically meaningful benefit from this therapy. We have had 5 patients who have been on therapy for more than 6 months, which is outstanding in this heavily pretreated advanced GIST cohort of patients.
Do these findings suggest a future for immunotherapy in patients with GISTs?
At this point, they do suggest that immunotherapy has a role in GIST. We still have another 20 patients to put onto the trial, so we are going to find out more information going forward. We will get a better sense of how many patients respond and how long they are responding, so we can plan future trials with novel immunotherapy combinations and study immunotherapy in conjunction with TKIs, which will be the future direction of these studies.
Are there any next steps following this trial?
We have seen one-third of patients receive benefit, not just in terms of disease shrinkage but a prolonged disease control, which is important for the group. The real question is why those patients are receiving benefit. In a separate ongoing study, we are looking at predictive biomarkers—trying to identify who is responding, why they are responding, or reasons why patients do not respond to immunotherapy.
Are there any significant challenges that you would like to see addressed in the next 5 to 10 years for the treatment of GIST?
There are several challenges that remain for GIST. It is one of these diseases that has been molecularly characterized. However, that has not told us everything because while we have found drugs that worked well, we are not curing patients. While there are some patients who get prolonged disease control and eradication, once you stop TKIs in patients with advanced disease, the disease comes back.
... to read the full story